Loading...
XSHG600201
Market cap973mUSD
Jan 08, Last price  
6.49CNY
1D
-1.37%
1Q
-5.26%
Jan 2017
-62.62%
Name

Jinyu Bio-Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:600201 chart
P/E
25.15
P/S
4.46
EPS
0.26
Div Yield, %
0.94%
Shrs. gr., 5y
-1.00%
Rev. gr., 5y
-3.37%
Revenues
1.60b
+4.55%
466,899,407552,597,984561,866,923702,180,147815,014,679685,494,694670,330,720576,140,310556,475,105671,382,9781,062,932,0251,246,505,8441,517,019,2831,901,010,2641,896,608,6301,126,782,2531,581,905,6321,776,317,8111,528,669,2561,598,225,460
Net income
284m
+34.64%
44,199,86012,281,76937,458,18792,925,47172,207,19966,473,720115,188,976149,438,394130,434,791250,883,061404,321,363479,727,738644,541,675870,094,412754,465,552221,041,634406,195,463382,286,663210,659,922283,630,790
CFO
415m
+20.36%
81,061,66528,290,477102,662,785136,094,806223,910,89800185,203,233102,946,417649,339,640585,186,590494,320,157756,123,716891,439,596422,460,842405,242,914699,612,782533,084,549344,650,092414,833,263
Dividend
Jul 15, 20240.08 CNY/sh
Earnings
May 27, 2025

Profile

Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sales of veterinary biological products in China. It offers vaccines for foot-and-mouth disease, highly pathogenic avian influenza, brucellosis, rabies, and swine fever for pigs, poultry, ruminants, and pets. The company was formerly known as Inner Mongolia Jinyu Group Co., Ltd. and changed its name to Jinyu Bio-technology Co., Ltd. in December 2015. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.
URL
http://www.jinyu.com.cn/
IPO date
Jan 15, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,598,225
4.55%
1,528,669
-13.94%
Cost of revenue
1,087,462
1,158,928
Unusual Expense (Income)
NOPBT
510,763
369,741
NOPBT Margin
31.96%
24.19%
Operating Taxes
38,734
45,443
Tax Rate
7.58%
12.29%
NOPAT
472,030
324,298
Net income
283,631
34.64%
210,660
-44.89%
Dividends
(66,807)
(120,538)
Dividend yield
0.57%
1.23%
Proceeds from repurchase of equity
185,031
(60,004)
BB yield
-1.58%
0.61%
Debt
Debt current
10,547
Long-term debt
5,470
615
Deferred revenue
364,836
370,490
Other long-term liabilities
1
1
Net debt
(2,110,908)
(1,705,762)
Cash flow
Cash from operating activities
414,833
344,650
CAPEX
(273,165)
Cash from investing activities
(740,111)
176,617
Cash from financing activities
111,376
FCF
525,564
318,221
Balance
Cash
1,749,468
1,452,372
Long term investments
366,909
264,551
Excess cash
2,036,466
1,640,490
Stockholders' equity
4,572,158
4,541,818
Invested Capital
3,986,044
4,061,872
ROIC
11.73%
7.72%
ROCE
8.47%
6.47%
EV
Common stock shares outstanding
1,087,330
1,087,330
Price
10.77
19.53%
9.01
-44.89%
Market cap
11,710,540
19.53%
9,796,840
-46.71%
EV
9,887,689
8,368,532
EBITDA
700,022
569,903
EV/EBITDA
14.12
14.68
Interest
342
4,815
Interest/NOPBT
0.07%
1.30%